TABLE 3.
Univariate analysis of factors associated with EFS and OS
| Event-Free Survival | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Variable | Number at risk | 3-year Event-Free Survival | 95% Confidence Interval | Log rank test P-value | 3-year Overall Survival | 95% Confidence Interval | Log rank test P-value |
|
| |||||||
| Age as a categorical variable | |||||||
|
| |||||||
| < 1 | 3 | 66.7% | ( 13.3%, 100.0% ) | 0.0008 | 66.7% | ( 13.3%, 100.0%) | <0.0001 |
|
| |||||||
| 1 – 9 | 47 | 25.0% | ( 11.6%, 38.4% ) | 43.7% | ( 28.9%, 58.4% ) | ||
|
| |||||||
| ≥ 10 | 129 | 2.5% | ( 0.0%, 5.3% ) | 18.8% | ( 11.9%, 25.8% ) | ||
|
| |||||||
| Race | |||||||
|
| |||||||
| Nonwhite | 29 | 6.9% | ( 0.0%, 16.1% ) | 0.2322 | 24.1% | ( 8.6%, 39.7% ) | 0.1233 |
|
| |||||||
| White | 132 | 10.6% | ( 4.9%, 16.2% ) | 28.6% | ( 20.6%, 36.6% ) | ||
|
| |||||||
| Unknown | 18 | 5.6% | ( 0.0%, 16.1% ) | 11.1% | ( 0.00%, 25.63% ) | ||
|
| |||||||
| Histology Subtype | |||||||
|
| |||||||
| Alveolar | 136 | 4.8% | ( 1.1%, 8.5% ) | 0.0122 | 23.9% | ( 16.6%, 31.3% ) | 0.0337 |
|
| |||||||
| Alveolar Fusion Status | |||||||
|
| |||||||
| Positive FOXO1 Fusion | 68 | 4.5% | ( 0.0%, 9.5% ) | 0.0367# | 28.4% | ( 17.6%, 39.2% ) | 0.0764# |
|
| |||||||
| PAX3-FOXO1 | 47 | 6.6% | ( 0.0%, 13.7% ) | 0.1039 | 34.8% | ( 21.0%, 48.6%) | 0.1184 |
| PAX7-FOXO1 | 5 | 0.0% | ( ., . ) | 0.0% | ( ., . ) | ||
| Unknown Partner-FOXO1 | 16 | 0.0% | ( ., . ) | 18.8% | (0 0%.,37.9%) | ||
|
| |||||||
| Negative FOXO1 Fusion | 3 | 0.0% | ( ., . ) | 0.0% | ( ., . ) | ||
|
| |||||||
| Unknown Fusion Status | 65 | 5.4% | ( 0.0%, 11.3% ) | 20.2% | ( 10.0%, 30.4% ) | ||
|
| |||||||
| Non-alveolar (Embryonal, Botryoid, Spindle, Other) | 43 | 24.6% | ( 10.6%, 38.5% ) | 33.4% | ( 18.6%, 48.2% ) | ||
|
| |||||||
| Primary Site | |||||||
|
| |||||||
| Favorable (Orbit, Head and Neck-non-PM, PM, GU B/P, GU non-B/P | 49 | 25.1% | ( 12.3%, 38.0% ) | 0.0013 | 35.6% | ( 21.6%, 49.5% ) | 0.0260 |
|
| |||||||
| Unfavorable (Extremity, other) | 123 | 3.8% | ( 0.2%, 7.4% ) | 24.0% | ( 16.3%, 31.8% ) | ||
|
| |||||||
| Unknown | 7 | 0.0% | ( ., . ) | 0.0% | ( ., . ) | ||
|
| |||||||
| T status | |||||||
|
| |||||||
| T1 | 11 | 9.1% | ( 0.0%, 26.1% ) | 0.8266 | 18.2% | ( 0.0%, 41.0% ) | 0.8935 |
|
| |||||||
| T2 | 167 | 9.5% | ( 4.7%, 14.2% ) | 26.83% | ( 19.9%, 33.8% ) | ||
|
| |||||||
| Size of the tumor | |||||||
|
| |||||||
| ≤ 5 cm | 51 | 8.0% | ( 0.5%, 15.6% ) | 0.8420 | 24.01% | ( 12.2%, 35.9% ) | 0.7630 |
|
| |||||||
| >5 cm | 128 | 10.0% | ( 4.4%, 15.6% ) | 27.0% | ( 19.0%, 35.0% ) | ||
|
| |||||||
| Number of Metastatic Sites | |||||||
|
| |||||||
| ≤ 2 | 68 | 15.4% | ( 6.6%, 24.2% ) | 0.0662 | 32.8% | ( 21.6%, 44.1% ) | 0.0476 |
|
| |||||||
| ≥ 3 | 110 | 5.5% | ( 0.8%, 10.1% ) | 21.7% | ( 13.7%, 29.8% ) | ||
|
| |||||||
| Additional Metastatic Sites | |||||||
|
| |||||||
| Bone Marrow Only | 22 | 9.4% | ( 4.9%, 13.9% ) | 26.1% | ( 19.5%, 32.8% ) | ||
|
| |||||||
| Bone | 100 | 6.4% | ( 1.0%, 11.8% ) | 0.4526 | 20.7% | ( 12.4%, 29.0% ) | 0.1204 |
|
| |||||||
| Lung | 70 | 7.2% | ( 0.4%, 14.1% ) | 0.9109 | 26.1% | ( 15.1%, 37.0% ) | 0.8038 |
|
| |||||||
| Lymph node | 81 | 6.8% | ( 1.1%, 12.6% ) | 0.1969 | 21.3% | ( 12.0%, 30.5% ) | 0.0814 |
|
| |||||||
| Oberlin Score | |||||||
|
| |||||||
| 1 | 10 | 40.0% | ( 9.6%, 70.4% ) | 0.0011 | 50.0% | ( 19.0%, 81.0% ) | 0.0012 |
|
| |||||||
| 2 | 34 | 26.1% | ( 10.6%, 41.7% ) | 40.5% | ( 23.5%, 57.5% ) | ||
|
| |||||||
| 3 | 65 | 6.0% | ( 0.0%, 12.6% ) | 27.1% | ( 15.8%, 38.5% ) | ||
|
| |||||||
| 4 | 63 | 0.0% | ( ., . ) | 16.5% | ( 7.2%, 25.9% ) | ||
|
| |||||||
| Radiation | |||||||
|
| |||||||
| Yes | 149 | 10.9% | ( 5.7%, 16.1% ) | <0.0001 | 28.9% | ( 21.4%, 36.3% ) | 0.0005 |
|
| |||||||
| No | 30 | 0.0% | ( ., . ) | 11.9% | ( 0.0%, 24.5% ) | ||
#
Fusion Positive compared to non-alveolar histology (Inclusive of fusion negative and fusion unknown)